|
CLINICA CAYANGA |
||
|
|
Sildenafil (Viagra) Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction |
|
|
Alzheimer's
Disease Arthritis Asthma Benign Prostatic Hypertrophy Chronic Lymphocytic Leukemia Coronary Artery Disease Depression Diabetes Mellitus Dyspepsia Erectile Dysfunction Fatty Liver Gallstone Hepatitis Hypertension Lung Cancer Mesothelioma Metabolic Syndrome Obesity Pneumonia Pregnancy Prostate Cancer Sinusitis Stroke Tinnitus |
Clinical Question: Does sildenafil (50 mg nightly for one year) can improve spontaneous erectile function (EF) in men with mild-to-moderate arteriogenic erectile dysfunction (ED) responsive to erectogenic treatment? Bottom Line: Sildenafil (viagra) nightly for one year resulted in ED regression that persisted well beyond the end of treatment, so that spontaneous EF was characterized as normal on the IIEF in most men. The results from this open-label, randomized trial warrant verification under double-blind, placebo-controlled conditions. Reference: Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Sommer F, Klotz T, Engelmann U. Asian J Androl. 2007 Jan;9(1):134-141 Study Design: Randomized Controlled Trial (prospective open-label trial) Synopsis: The authors test the hypothesis that sildenafil (50 mg nightly for one year) can improve spontaneous erectile function (EF) in men with mild-to-moderate arteriogenic erectile dysfunction (ED) responsive to erectogenic treatment. They did a prospective open-label trial, 112 men with ED were randomized to sildenafil 50 mg nightly or sildenafil 50 or 100 mg as needed for 12 months, followed by one-month and 6-month non-medicated periods. Non-randomized, non-medicated men with ED were also assessed. The EF domain of the International Index of Erectile Function (IIEF EF) and the peak systolic velocity (PSV) of penile cavernous arteries were used to measure the efficacy. After sildenafil treatment and a subsequent non-medicated month, IIEF EF was normal in 29 of 48 (60.4%, 95% confidence interval [CI]: 45.3-74.2%) of the nightly group vs. 4 of 49 (8.2%, 95% CI: 2.3-19.6%) of the as-needed group. PSV improved by 11.2 cm/s (95% CI: 4.7-21.4; P=0.012) in the nightly group but only by 3.4 cm/s (-5.1-14.7; P=0.435) in the as-needed group. IIEF EF normalized in 1 of 18 (5.6%, 95% CI: 0.1-27.3%) non-medicated men and the PSV declined slightly. Six months after treatment, the IIEF EF remained normal and PSV was stabilized in most (28/29, 97%) nightly group men who had initially normalized. |
|
|
Patient Information |
||
| Health For Life | ||
|
Medical Library |
||
|
Breaking Medical News Clinical Tools Coronary Risk Profile Dermatology Diabetes Corner Evidence-Based Medicine Free Medical Books Free Medical Journal History Taking and Physical Examination Hows on Making Diagnostic Examination Medical Journal (popular) Medical Organizations Medical Professional News Neurological and Psychiatric Problems in Clinical Practice Palm Tools Medical Notes Medical Physiology (Lecture) Medical Resources Medical Search Online Clinical Calculator Scientific Meeting |
||
| Online Sari-Sari Store | ||
Please
support Clinica Cayanga Medical Resources by purchasing gift items
at  |
||
|
Home | Introduction | Scheduling a Visit| Laboratory Work | Reaching Us | Map to our Office | About the Doctors |
||